Home / Business and Economy / Cipla inks Keytruda biosimilar deal
Cipla inks Keytruda biosimilar deal
3 Sep
Summary
- Cipla's US unit partners with Qilu Pharmaceutical.
- Exclusive license secured for Keytruda biosimilar.
- Deal targets the United States market.
Cipla's U.S. subsidiary has forged an exclusive partnership with China's Qilu Pharmaceutical. This strategic alliance focuses on licensing a biosimilar version of Merck's prominent cancer drug, Keytruda.
The agreement specifically targets the United States market, aiming to introduce a more accessible alternative to the existing cancer therapy. This move by Cipla's U.S. unit highlights the growing importance of biosimilars in expanding patient access to critical medications.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
